Rua Bioscience Limited (“RUA”) advises that the 3 for 4 pro-rata renounceable rights offer (“Rights Offer”) to raise up to $3.1 million opens today at 2pm at www.shareoffer.co.nz/rua.
A copy of the Offer Document was lodged to the NZX on 6 November 2024.
The Rights Offer is available to eligible shareholders with a registered address in New Zealand or Australia at 5.00pm NZST on Wednesday, 13 November 2024 (“Eligible Shareholders”). Eligible Shareholders are being invited to subscribe for new shares at an offer price of NZ$0.025c per new share.
Eligible Shareholders who wish to participate should apply and pay via www.shareoffer.co.nz/rua by Tuesday, 26 November 2024. The Rights Offer is structured to provide all Eligible Shareholders with a fair opportunity to participate while Eligible Shareholders who take up their rights in full may also apply for additional shares at the same price.
The Rights Offer is critical to supporting Rua’s ongoing business with the proceeds intended to fund working capital to support sales growth and Rua’s immediate cash flow requirements.
Further information
The Offer Document and other important information about the Rights Offer is available on the website established for the Entitlement Offer at www.shareoffer.co.nz/rua. Eligible shareholders are encouraged to visit that website and read all the materials available or referred to on it (including the Offer Document, investor presentation and market announcement published by Rua Bioscience on 6th November (together, the “Offer Materials”) before making a decision whether to apply online from Thursday, 14 November 2024.
Additional information on Rua Bioscience can be found at
www.ruabio.com/capital-raise-november-2024
Shareholders who have any questions about the Rights Offer are encouraged to seek financial, investment or other professional advice from a qualified professional adviser.
ENDS
The person who authorised this announcement:
Paul Naske
Chief Executive Officer
[email protected]
+64 21 445154
Growth-stage venture market at its most 'investor friendly' since 2013 - Icehouse.
Private equity, private credit and long short equity funds are on offer.
Genesis argues it is undervalued; at least one analyst agrees.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details